Last updated on July 2019

A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea


Brief description of study

To assess the efficacy and safety of S5G4T-1 compared to S5G4T-1 Vehicle when applied once daily for 12 weeks in patients with papulopustular rosacea

Detailed Study Description

In this Phase 3, double blind, vehicle controlled study, patients will be admitted into this multi center, double blind, randomized, vehicle controlled, parallel group pivotal study only after a written informed consent has been obtained and after all inclusion/exclusion criteria have been met. Male and female patients at least 18 years of age with moderate or severe papulopustular rosacea will be eligible for enrollment for daily treatment with S5G4T-1 or its vehicle for 12 weeks.

Clinical Study Identifier: NCT03448939

Find a site near you

Start Over

Sol-Gel site 101

Tampa, FL United States
  Connect »

Sol-Gel site 501

Tampa, FL United States
  Connect »